Business Capital Delivers $5.5 Million Financing for Wedderspoon
January 14, 2020 07:00 ET
|
Business Capital
SAN FRANCISCO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Business Capital structured and delivered a $5.5MM working capital facility for Wedderspoon, the largest seller of Manuka honey and its portfolio of...
Animal Drugs Market value to hit $41 billion by 2025: Global Market Insights, Inc.
December 01, 2019 20:00 ET
|
Global Market Insights, Inc
Selbyville, Delaware, Dec. 01, 2019 (GLOBE NEWSWIRE) -- Global Animal Drugs Market is set to cross USD 41 billion by 2025, according to a new research report by Global Market Insights, Inc....
Results from Celtaxsys’ Acebilustat Phase 2 Trial in Cystic Fibrosis Patients Showing Clinically Meaningful Improvement in Pulmonary Exacerbations Presented at the North American Cystic Fibrosis Conference
October 22, 2018 08:00 ET
|
Celtaxsys, Inc.
ATLANTA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...
Data from Celtaxsys’ Acebilustat Phase 2 Trial addressing Lung Inflammation in CF Patients to be presented at the North American Cystic Fibrosis Conference
October 11, 2018 08:00 ET
|
Celtaxsys, Inc.
ATLANTA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Full results from the recently completed Phase 2 trial (EMPIRE-CF) of Celtaxsys’ acebilustat will be presented at the North American Cystic Fibrosis...
Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients
August 02, 2018 08:00 ET
|
Celtaxsys, Inc.
-Acebilustat is the first novel anti-inflammatory molecule evidencing the potential to reduce frequency of pulmonary exacerbations and prolong time to first exacerbation in CF patients --Celtaxsys,...
Trivedi Global, Inc. and Kathryn Sweas Announce Research Results of a Biofield Energy Treated Nutraceutical to Mitigate Inflammation and Autoimmune Disorders
July 10, 2018 10:00 ET
|
Trivedi Global, Inc.
Portland, Oregon, USA, July 10, 2018 (GLOBE NEWSWIRE) -- Kathryn Sweas, an evidence-based energy healer, today announces the impact of a biofield energy treated nutraceutical to increase immunity...
Trivedi Global, Inc. and Maire Mayne Announce Research Results on the Impact of an Energy Treated Nutraceutical for Reducing Autoimmune and Inflammatory Disorders
July 09, 2018 12:34 ET
|
Trivedi Global, Inc.
London, United Kingdom, July 09, 2018 (GLOBE NEWSWIRE) -- Maire Mayne, an energy healer with scientifically validated abilities, today announces the outcome of preclinical research on a proprietary...
Trivedi Global, Inc. in Association with Roland Piedad, Announces Research Results on the Impact of a Biofield Energy Treated Nutraceutical to Reduce Inflammation and Autoimmune Disorders
June 06, 2018 09:00 ET
|
Trivedi Global, Inc.
Los Angeles, California, USA, June 06, 2018 (GLOBE NEWSWIRE) -- Roland Piedad, an evidence-based healer, today announces research results on the significant impact of a proprietary biofield energy...
Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July
May 17, 2018 08:00 ET
|
Celtaxsys, Inc.
ATLANTA, May 17, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...
UPDATE -- Sciadonics, Inc. Launches DELTA-5™ Oil by SciaEssentials™
April 04, 2018 11:53 ET
|
SciaEssentials
WAYZATA, Minn., April 04, 2018 (GLOBE NEWSWIRE) -- Launched in March 2018, DELTA-5 by SciaEssentials is a cutting-edge topical oil containing sciadonic acid, a type of fatty acid that has...